Medicinal Chemistry, Trinity St. James's Cancer Institute, Trinity Translational Medicine Institute, St. James's Hospital, Trinity College Dublin, The University of Dublin, Dublin 8, Ireland.
CQC, Coimbra Chemistry Center, University of Coimbra, Rua Larga 3004-535, Coimbra, Portugal.
Biomacromolecules. 2024 Jan 8;25(1):24-42. doi: 10.1021/acs.biomac.3c00591. Epub 2023 Oct 27.
Photodynamic therapy (PDT) is an anticancer therapy with proven efficacy; however, its application is often limited by prolonged skin photosensitivity and solubility issues associated with the phototherapeutic agents. Injectable hydrogels which can effectively provide intratumoral delivery of photosensitizers with sustained release are attracting increased interest for photodynamic cancer therapies. However, most of the hydrogels for PDT applications are based on systems with high complexity, and often, preclinical validation is not provided. Herein, we provide a simple and reliable pH-sensitive hydrogel formulation that presents appropriate rheological properties for intratumoral injection. For this, (), which is one of the most potent clinical photosensitizers, was chemically modified to introduce functional groups that act as cross-linkers in the formation of chitosan-based hydrogels. The introduction of -COOH groups resulted in a water-soluble derivative, named , that was the most promising candidate. Although was not internalized by the target cells, its extracellular activation caused effective damage to the cancer cells, which was likely mediated by lipid peroxidation. The injection of the hydrogel containing in the tumors was monitored by high-frequency ultrasounds and fluorescence imaging which confirmed the sustained release of for at least 72 h. Following local administration, light exposure was conducted one (single irradiation protocol) or three (multiple irradiation protocols) times. The latter delivered the best therapeutic outcomes, which included complete tumor regression and systemic anticancer immune responses. Immunological memory was induced as ∼75% of the mice cured with our strategy rejected a second rechallenge with live cancer cells. Additionally, the failure of PDT to treat immunocompromised mice bearing tumors reinforces the relevance of the host immune system. Finally, our strategy promotes anticancer immune responses that lead to the abscopal protection against distant metastases.
光动力疗法(PDT)是一种已被证实具有疗效的抗癌疗法;然而,其应用常常受到与光疗剂相关的皮肤光敏感性和溶解度问题的限制。可有效提供具有持续释放的光敏剂的肿瘤内递药的可注射水凝胶,越来越受到光动力癌症治疗的关注。然而,大多数用于 PDT 应用的水凝胶基于具有高复杂性的系统,并且通常未提供临床前验证。在此,我们提供了一种简单可靠的 pH 敏感水凝胶配方,具有适合肿瘤内注射的适当流变学性质。为此,(),它是最有效的临床光敏剂之一,被化学修饰以引入在壳聚糖基水凝胶形成中起交联剂作用的官能团。-COOH 基团的引入导致水溶性衍生物,命名为,这是最有前途的候选物。尽管 没有被靶细胞内化,但它的细胞外激活导致对癌细胞的有效损伤,这可能是通过脂质过氧化介导的。含有 的水凝胶在肿瘤中的注射通过高频超声和 荧光成像进行监测,证实了 至少 72 小时的持续释放。局部给药后,进行一次(单次辐照方案)或三次(多次辐照方案)光照射。后者提供了最佳的治疗效果,包括完全肿瘤消退和全身抗癌免疫反应。我们的策略诱导了免疫记忆,因为大约 75%用我们的策略治愈的小鼠拒绝了第二次用活癌细胞进行的再挑战。此外,PDT 未能治疗携带肿瘤的免疫功能低下的小鼠,这加强了宿主免疫系统的相关性。最后,我们的策略促进了抗癌免疫反应,导致对远处转移的肿瘤外保护。